SAGE Therapeutics Receives U.S. Orphan Drug Designation for Lead Compound SAGE-547 to Treat Status Epilepticus SAGE Therapeutics , a biopharmaceutical company developing novel medicines to treat life-threatening, rare central nervous system disorders, today announced the U.S. Food and Drug Administration has granted orphan drug designation to its neuroactive steroid, SAGE-547, for the treatment of status epilepticus.
May 1, 2014 - Business Wire via Yahoo! Finance